ZACKS·2025-10-17 14:41Group 1 - Beam Therapeutics Inc. (BEAM) has shown a year-to-date performance increase of approximately 4%, outperforming the average gain of 0.4% in the Medical sector [4] - The Zacks Consensus Estimate for BEAM's full-year earnings has risen by 1.4% over the past quarter, indicating improved analyst sentiment and earnings outlook [4] - Beam Therapeutics Inc. holds a Zacks Rank of 2 (Buy), suggesting it has characteristics favorable for outperforming the market in the near term [3] Group 2 - Beam Therapeutics Inc. is part of the Medical - Biomedical and Genetics industry, which has an average gain of 8.9% year-to-date, indicating that BEAM is slightly underperforming its industry [6] - Humana (HUM) is another Medical stock that has outperformed the sector with a year-to-date increase of 5.4% and also holds a Zacks Rank of 2 (Buy) [5] - The Medical group consists of 956 companies and is currently ranked 5 in the Zacks Sector Rank, reflecting a strong overall performance [2]